BACKGROUND: Pathogenic mutations in the leucine-rich repeat kinase 2 gene (LRRK2) have been found to cause typical, later-onset Parkinson disease (PD). Although G2019S is the most common mutation, other mutations have also been reported. It is critical to catalog the types of mutations found in LRRK2 that can cause PD, so as to provide insight regarding disease susceptibility and potential novel treatments. METHODS: We performed a comprehensive study of all 51 exons of the LRRK2 gene in one PD patient from each of 88 multiplex PD families who had the highest family-specific multipoint lod score at the LRRK2 locus from a cohort of 430 PD families without the G2019S mutation. RESULTS: Five families (5.7%) harbored what seem to be novel, pathogenic mutations (L1795F, I1192V, E10K, E334K, Q1111H). Three of these apparent mutations were in known, functional domains of the LRRK2 protein, where other studies have also identified disease producing mutations. However, two of the novel variants were found in the N-terminal region of LRRK2, where no pathogenic substitutions have yet been reported. Similar to previous studies, all subjects with an LRRK2 mutation had classic symptoms of PD and typical, later age at onset. CONCLUSIONS: We have identified five novel variants in LRRK2, with two of these in the N-terminal region of LRRK2, where no pathogenic substitutions have been previously reported. If confirmed to be causative, these mutations would broaden the potential mechanisms whereby mutations in LRRK2 result in Parkinson disease.
BACKGROUND: Pathogenic mutations in the leucine-rich repeat kinase 2 gene (LRRK2) have been found to cause typical, later-onset Parkinson disease (PD). Although G2019S is the most common mutation, other mutations have also been reported. It is critical to catalog the types of mutations found in LRRK2 that can cause PD, so as to provide insight regarding disease susceptibility and potential novel treatments. METHODS: We performed a comprehensive study of all 51 exons of the LRRK2 gene in one PDpatient from each of 88 multiplex PD families who had the highest family-specific multipoint lod score at the LRRK2 locus from a cohort of 430 PD families without the G2019S mutation. RESULTS: Five families (5.7%) harbored what seem to be novel, pathogenic mutations (L1795F, I1192V, E10K, E334K, Q1111H). Three of these apparent mutations were in known, functional domains of the LRRK2 protein, where other studies have also identified disease producing mutations. However, two of the novel variants were found in the N-terminal region of LRRK2, where no pathogenic substitutions have yet been reported. Similar to previous studies, all subjects with an LRRK2 mutation had classic symptoms of PD and typical, later age at onset. CONCLUSIONS: We have identified five novel variants in LRRK2, with two of these in the N-terminal region of LRRK2, where no pathogenic substitutions have been previously reported. If confirmed to be causative, these mutations would broaden the potential mechanisms whereby mutations in LRRK2 result in Parkinson disease.
Authors: Ignacio F Mata; Greggory J Wilhoite; Dora Yearout; Justin A Bacon; Mario Cornejo-Olivas; Pilar Mazzetti; Victoria Marca; Olimpio Ortega; Oscar Acosta; Carlos Cosentino; Luis Torres; Angel C Medina; Carolina Perez-Pastene; Fernando Díaz-Grez; Carles Vilariño-Güell; Pablo Venegas; Marcelo Miranda; Osvaldo Trujillo-Godoy; Luis Layson; Rodrigo Avello; Elena Dieguez; Victor Raggio; Federico Micheli; Claudia Perandones; Victoria Alvarez; Juan Segura-Aguilar; Matthew J Farrer; Cyrus P Zabetian; Owen A Ross Journal: Parkinsonism Relat Disord Date: 2011-05-31 Impact factor: 4.891
Authors: Chen Yao; Rabih El Khoury; Wen Wang; Tara A Byrd; Elizabeth A Pehek; Colin Thacker; Xiongwei Zhu; Mark A Smith; Amy L Wilson-Delfosse; Shu G Chen Journal: Neurobiol Dis Date: 2010-04-09 Impact factor: 5.996
Authors: W C Nichols; N Pankratz; D K Marek; M W Pauciulo; V E Elsaesser; C A Halter; A Rudolph; J Wojcieszek; R F Pfeiffer; T Foroud Journal: Neurology Date: 2008-11-05 Impact factor: 9.910
Authors: Nathan Pankratz; Karen S Marder; Cheryl A Halter; Alice Rudolph; Cliff W Shults; William C Nichols; Tatiana Foroud Journal: Mov Disord Date: 2008-11-15 Impact factor: 10.338
Authors: W C Nichols; D K Kissell; N Pankratz; M W Pauciulo; V E Elsaesser; K A Clark; C A Halter; A Rudolph; J Wojcieszek; R F Pfeiffer; T Foroud Journal: Neurology Date: 2009-03-11 Impact factor: 9.910
Authors: N Pankratz; D K Kissell; M W Pauciulo; C A Halter; A Rudolph; R F Pfeiffer; K S Marder; T Foroud; W C Nichols Journal: Neurology Date: 2009-07-28 Impact factor: 9.910
Authors: Cyrus P Zabetian; Mitsutoshi Yamamoto; Alexis N Lopez; Hiroshi Ujike; Ignacio F Mata; Yuishin Izumi; Ryuji Kaji; Hirofumi Maruyama; Hiroyuki Morino; Masaya Oda; Carolyn M Hutter; Karen L Edwards; Gerard D Schellenberg; Debby W Tsuang; Dora Yearout; Eric B Larson; Hideshi Kawakami Journal: Mov Disord Date: 2009-05-15 Impact factor: 10.338
Authors: Jeanne C Latourelle; Nathan Pankratz; Alexandra Dumitriu; Jemma B Wilk; Stefano Goldwurm; Gianni Pezzoli; Claudio B Mariani; Anita L DeStefano; Cheryl Halter; James F Gusella; William C Nichols; Richard H Myers; Tatiana Foroud Journal: BMC Med Genet Date: 2009-09-22 Impact factor: 2.103